ATHX biopharma stock chatter

ATHX biopharma stock chatter

athx ticker athx ticker

Only 8 people have searched for ATHX on MarketBeat in the last 30 days. This is a decrease of -69% compared to the previous 30 days. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist.

athx ticker

Athersys has only been the subject of 1 research reports in the past 90 days. Quotes displayed in real-time or delayed by at least 15 minutes. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements.

Athersys Granted Clinical Type B Meeting with FDA for MASTERS-2 Clinical Trial Protocol Discussion

ATHX underperformed the US Biotechs industry which returned -1% over the past year. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. The industry with the best average Zacks Rank would be considered the top industry , which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. The Zacks Industry Rank assigns a rating to each of the 265 X Industries based on their average Zacks Rank.

Artivion Stock (NYSE:AORT), Quotes and News Summary – Benzinga

Artivion Stock (NYSE:AORT), Quotes and News Summary.

Posted: Fri, 28 Jan 2022 06:30:49 GMT [source]

Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH. initiated coverage on Athersys in a research note on Thursday. Alliance Global Partners initiated coverage on Athersys in a research note on Monday, March 6th.

Athersys, Inc. Announces Pricing of $5.5 Million Public Offering

Shares of Athersys Inc. shot up 26.5% in premarket trading Monday, after the company said it has received Food and Drug Administration authorization to start a phase 2/3 trial to assess safety and efficacy of its MultiSte… 1 employees have rated Athersys Chief Executive tsla stock price quote & news Officer William (B.J.) Lehmann on William (B.J.) Lehmann has an approval rating of 100% among the company’s employees. This puts William (B.J.) Lehmann in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.52% per year. These returns cover a period from January 1, 1988 through February 6, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month.

athx ticker

Its revenue has been derived from corporate collaborations, license agreements, and government grants. 2 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Athersys in the last year. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should “hold” ATHX shares.

Amkor Technology, Athersys, Google, Jabil, KB Home

They set a “buy” rating and a $5.50 price target for the company. Athersys, Inc engages in the discovery and development of therapies designed to extend and enhance to quality of human life. BOSTON — Partners Athersys Inc. and Angiotech Pharmaceuticals both gained ground in early Thursday, the day after the company announced positive Phase I data from a study for their stem cell product MultiS… BOSTON — Biodel Inc. led drug stocks south early Tuesday as shares of the biotech company fell on news that the U.S. Food and Drug Administration has issued a warning letter to one of its contract product ma… According to 6 analysts, the average rating for ATHX stock is “Sell.” The 12-month stock price forecast is $5.61, which is an increase of 328.24% from the latest price.

Market Cap is calculated by multiplying the number of shares outstanding by the stock’s price. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.Dividend YieldA company’s dividend expressed as a percentage of its current stock price. Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATHX, but not buy additional shares or sell existing shares. Athersys saw a drop in short interest during the month of February. As of February 28th, there was short interest totaling 1,140,000 shares, a drop of 8.1% from the February 13th total of 1,240,000 shares. Based on an average daily trading volume, of 321,200 shares, the days-to-cover ratio is presently 3.5 days.

Nasdaq Drops 200 Points; Meta Platforms Shares Jump

You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.

CDXC Stock Forecast, Price & News (ChromaDex) – MarketBeat

CDXC Stock Forecast, Price & News (ChromaDex).

Posted: Sat, 27 Aug 2016 13:59:14 GMT [source]

On average, they predict the company’s stock price to reach $5.88 in the next twelve months. This suggests a possible upside of 316.7% from the stock’s current price. View analysts price targets for ATHX or view top-rated stocks among Wall Street analysts. It is focused on developing novel and proprietary therapies in the areas where there is an unmet medical need, particularly in the regenerative medicine area. Its current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders and certain pulmonary conditions.

It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio. 2 equities research analysts have issued twelve-month target prices for Athersys’ shares. Their ATHX share price forecasts range from $5.50 to $6.25.

Athersys’s stock shoots up after FDA OKs study for COVID-19-induced respiratory distress treatment

BOSTON — Shares of many of the publicly-traded stem cell researchers lost ground Tuesday, the day after a federal judge blocked a recent government decision to expand federal funding for certain types of embr… BOSTON — A federal judge on Wednesday upheld the Obama Administration’s decision to restore federal funding for certain types of embryonic stem-cell research, according to reports. Shares of Athersys reverse split before market open on Monday, August 29th 2022.

It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Shares of stem-cell researchers regain ground, after being pushed down earlier in the week on investor concerns that a court ruling against the federal funding of embryonic stem-cell research would negatively impact the fl… BOSTON — A federal appeals court on Thursday ruled that federal funding of embryonic stem-cell research projects will continue while a recent judge’s ruling against such funding is under appeal, according to…

Historical and current end-of-day data provided by FACTSET. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.

AIG, Google and Jabil are all making notable moves in the U.S. stock market today. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023. Sign-up to receive the latest news and ratings for Athersys and its competitors with MarketBeat’s FREE daily newsletter.

  • Intraday Data provided by FACTSET and subject to terms of use.
  • This is a decrease of -69% compared to the previous 30 days.
  • That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
  • Based on an average daily trading volume, of 321,200 shares, the days-to-cover ratio is presently 3.5 days.
  • Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.

The 1-25 reverse split was announced on Monday, August 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Represents the company’s profit divided by the outstanding shares of its common stock. The technique has proven to be very useful for finding positive surprises. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest.

65.0% of employees surveyed would recommend working at Athersys to a friend. Since then, ATHX shares have increased by 67.9% and is now trading at $1.41. Athersys has a short interest ratio (“days to cover”) of 3.5, which is generally considered an acceptable ratio of short interest to trading volume. The company’s average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.

Appointment Form